ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

RemeGen and Innovent Biologics side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

RemeGenInnovent Biologics
studies on the registry83218
open to participants now4259
phase 3 studies under way1823
reach primary completion within a year536
programswith a study of their own in two years1040

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseRemeGenInnovent Biologics
Phase 100%

Innovent Biologics: 14 of its 40 programs at phase 1

  1. IBI3033phase 1
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. Anti-CEACAM5 Antibody-drug Conjugate IBI3020phase 1
  5. IBI115phase 1

and 9 more — sign in to see them all

35%
Phase 2

RemeGen: 5 of its 10 programs at phase 2

  1. Anti-c-Met/MMAE ADC RC108phase 2
  2. ABBV-1480phase 2
  3. RC278phase 2
  4. RC288phase 2
  5. telisotuzumab adizutecanphase 2
50%

Innovent Biologics: 10 of its 40 programs at phase 2

  1. IBI3016phase 2
  2. telitaciceptphase 2
  3. IBI355phase 2
  4. IBI3002phase 2
  5. IBI3011phase 2

and 5 more — sign in to see them all

25%
Phase 3

RemeGen: 5 of its 10 programs at phase 3

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. telitaciceptphase 3
  4. RC28-E proteinphase 3
  5. tislelizumabphase 3
50%
38%
Approved, new studies00%

Innovent Biologics: 1 of its 40 programs at approved, new studies

  1. Teprotumumab N01approved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
RemeGen3 readouts · 3 phase 3·

RemeGen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. disitamab vedotinphase 3 · Dec 0 · NCT06221748
  2. telitaciceptphase 3 · Dec 31 · NCT07249632
····

RemeGen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. RC148phase 3 · May 12 · NCT07462143
·····
Innovent Biologics18 readouts · 4 phase 3

Innovent Biologics, Nov ’26: 1 program whose next study reaches primary completion

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3 · Nov 30 · NCT07122687

Innovent Biologics, Dec ’26: 6 programs whose next study reaches primary completion, 3 in phase 3

  1. arcotatug tavatecanphase 3 · Dec 30 · NCT06238843
  2. GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003phase 3 · Dec 31 · NCT07764861
  3. IBI302phase 3 · Dec 31 · NCT06908876
  4. IBI3026early phase 1 · Dec 31 · NCT07327632
  5. IBI311phase 3 · Dec 31 · NCT07113262

and 1 more — sign in to see them all

Innovent Biologics, Jan ’27: 3 programs whose next study reaches primary completion

  1. IBI3016phase 2 · Jan 30 · NCT07838220
  2. IBI3034phase 1 · Jan 31 · NCT07886476
  3. telitaciceptphase 2 · Jan 31 · NCT07886476

Innovent Biologics, Feb ’27: 2 programs whose next study reaches primary completion

  1. IBI3042phase 1 · Feb 3 · NCT07842393
  2. IBI3033phase 1 · Feb 10 · NCT07549984

Innovent Biologics, Mar ’27: 1 program whose next study reaches primary completion

  1. IBI3002phase 2 · Mar 23 · NCT07399067

Innovent Biologics, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tigulixostatphase 3 · Apr 30 · NCT07414394

Innovent Biologics, May ’27: 1 program whose next study reaches primary completion

  1. IBI3011phase 2 · May 11 · NCT07842497

Innovent Biologics, Jun ’27: 2 programs whose next study reaches primary completion

  1. IBI3031phase 1 · Jun 15 · NCT07622368
  2. IBI3028phase 1 · Jun 30 · NCT07589205

Innovent Biologics, Jul ’27: 1 program whose next study reaches primary completion

  1. IBI3035phase 1 · Jul 30 · NCT07591519
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

RemeGen

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Innovent Biologics

New programs 4

  • IBI3043phase 1 · first study · Oct 22
  • IBI3034phase 1 · first study · Oct 8 · Glomerulonephritis, IGA
  • telitaciceptphase 2 · first study · Sep 13 · Lupus Erythematosus, Systemic
  • IBI3046phase 1 · first study · Sep 3 · Obesity

Reached a new phase 2

  • IBI3011phase 2 · Sep 14 · Gout
  • IBI355phase 2 · Sep 13 · Sjogren's Syndrome

Study stopped 1

  • IBI356phase 2 · terminated Oct 27 · none of its studies left running“Sponsor Decision” · NCT07330934

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionRemeGenInnovent Biologics
Carcinoma, Non-Small-Cell Lungboth · compare here

RemeGen in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. tislelizumabphase 3
  4. Anti-c-Met/MMAE ADC RC108phase 2
  5. ABBV-1480phase 2

and 1 more — sign in to see them all

Their studies: RemeGen’s studies of Carcinoma, Non-Small-Cell Lung in search

Innovent Biologics in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3
  2. sintilimabphase 3
  3. gimeracilphase 2
  4. Oxonic Acidphase 2
  5. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsboth · compare here

RemeGen in Colorectal Neoplasms: 2 programs

  1. RC148phase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Colorectal Neoplasms in search

Stomach Neoplasmsboth · compare here

RemeGen in Stomach Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. tislelizumabphase 3

Their studies: RemeGen’s studies of Stomach Neoplasms in search

Innovent Biologics in Stomach Neoplasms: 4 programs

  1. sintilimabphase 3
  2. gimeracilphase 2
  3. Oxonic Acidphase 2
  4. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Stomach Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

RemeGen in Carcinoma, Hepatocellular: 2 programs

  1. tislelizumabphase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Carcinoma, Hepatocellular in search

Innovent Biologics in Carcinoma, Hepatocellular: 2 programs

  1. sintilimabphase 3
  2. Anti-CTLA-4 Monoclonal Antibody IBI310phase 3

Their studies: Innovent Biologics’ studies of Carcinoma, Hepatocellular in search

Breast Neoplasmsboth · compare here

RemeGen in Breast Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3

Their studies: RemeGen’s studies of Breast Neoplasms in search

Innovent Biologics in Breast Neoplasms: 1 program

  1. Anti-HER2 Antibody-drug Conjugate IBI354phase 3

Their studies: Innovent Biologics’ studies of Breast Neoplasms in search

Glomerulonephritis, IGAboth · compare here

RemeGen in Glomerulonephritis, IGA: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Glomerulonephritis, IGA in search

Innovent Biologics in Glomerulonephritis, IGA: 2 programs

  1. telitaciceptphase 2
  2. IBI3034phase 1

Their studies: Innovent Biologics’ studies of Glomerulonephritis, IGA in search

Sjogren's Syndromeboth · compare here

RemeGen in Sjogren's Syndrome: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Sjogren's Syndrome in search

Innovent Biologics in Sjogren's Syndrome: 2 programs

  1. telitaciceptphase 2
  2. IBI355phase 2

Their studies: Innovent Biologics’ studies of Sjogren's Syndrome in search

Esophageal Squamous Cell Carcinomaboth · compare here

RemeGen in Esophageal Squamous Cell Carcinoma: 1 program

  1. tislelizumabphase 3

Their studies: RemeGen’s studies of Esophageal Squamous Cell Carcinoma in search

Innovent Biologics in Esophageal Squamous Cell Carcinoma: 1 program

  1. sintilimabphase 3

Their studies: Innovent Biologics’ studies of Esophageal Squamous Cell Carcinoma in search

Lupus Erythematosus, Systemicboth · compare here

RemeGen in Lupus Erythematosus, Systemic: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Lupus Erythematosus, Systemic in search

Innovent Biologics in Lupus Erythematosus, Systemic: 1 program

  1. telitaciceptphase 2

Their studies: Innovent Biologics’ studies of Lupus Erythematosus, Systemic in search

Lymphoma, Follicularboth · compare here

RemeGen in Lymphoma, Follicular: 1 program

  1. telitaciceptphase 3

Their studies: RemeGen’s studies of Lymphoma, Follicular in search

Innovent Biologics in Lymphoma, Follicular: 1 program

  1. telitaciceptphase 2

Their studies: Innovent Biologics’ studies of Lymphoma, Follicular in search

Macular Degenerationboth · compare here

RemeGen in Macular Degeneration: 1 program

  1. RC28-E proteinphase 3

Their studies: RemeGen’s studies of Macular Degeneration in search

Innovent Biologics in Macular Degeneration: 1 program

  1. IBI302phase 3

Their studies: Innovent Biologics’ studies of Macular Degeneration in search

Macular Edemaboth · compare here

RemeGen in Macular Edema: 1 program

  1. RC28-E proteinphase 3

Their studies: RemeGen’s studies of Macular Edema in search

Innovent Biologics in Macular Edema: 1 program

  1. IBI302phase 3

Their studies: Innovent Biologics’ studies of Macular Edema in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: RemeGen 5 of 10 · Innovent Biologics 16 of 40 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.